KOD Reddit Mentions | ChartExchange

Thanks for all the encouragement on the last effort. I took your suggested stocks seriously and I've spent quite a bit of time trying to fine tune the algorithm that looks at sector, runway, phase, etc. I knew things had improved quite a bit when I saw SLS rise to the top.
The tool analyzes 175 biotech names and I'll share the top 20 here. If you're not seeing your favorite, let me know which it is and I'll see where (if) it ranks and why it's located where it landed.
2 things to know...
1. There's so much more work to do. It's not ready to be released to the public and I'm fully expecting major mistakes. I’m making progress but 175 biotech tickers and an accurate analysis and ranking takes work.
2. IGNORE THE CONFIDENCE SCORE: this is the confidence in the scraped, calculated data - NOT the confidence that the company will be acquired. The next steps for the tool are to backtest acquisitions from 2018-2022 to produce a calibration curve using Platt or Isotonic calibration.

Here's the top 20:

Biotech M&A Engine - Top 20 Overall
Generated: Jun 28, 2026
1. SLS - Sellas Life Sciences Group Inc | Score 0.537 | Confidence 100%
Why here: Final-event Phase III readout proximity (78/80); specific event count evidence; Oncology / hematology strategic segment; sweet spot at $1.5B; financing pressure (3.7 qtrs).
2. MLTX - MoonLake Immunotherapeutics | Score 0.463 | Confidence 100%
Why here: Phase III HS Week 52 data / regulatory path; source-backed evidence; Immunology / rare inflammation strategic segment; sweet spot at $1.4B; very short runway (1.7 qtrs).
3. ANNX - Annexon Inc | Score 0.463 | Confidence 100%
Why here: Phase III positive/near-term catalyst; provisional evidence; Immunology / rare inflammation strategic segment; sweet spot at $870M; very short runway (1.3 qtrs).
4. INBX - Inhibrx Biosciences Inc | Score 0.444 | Confidence 88%
Why here: Mixed catalyst: Phase 2/3 HNSCC PFS update; source-backed evidence; Oncology / hematology strategic segment; sweet spot at $1.3B; very short runway (1.7 qtrs).
5. SVRA - Savara Inc | Score 0.426 | Confidence 100%
Why here: PDUFA/regulatory catalyst within 12 months; bucketed evidence; Immunology / rare inflammation strategic segment; sweet spot at $1.0B; financing pressure (2.0 qtrs).
6. SNDX - Syndax Pharmaceuticals Inc | Score 0.407 | Confidence 100%
Why here: Phase III readout within 12 months; provisional evidence; Oncology / hematology strategic segment; sweet spot at $1.6B; very short runway (1.3 qtrs).
7. IOVA - Iovance Biotherapeutics Inc | Score 0.389 | Confidence 95%
Why here: Oncology / hematology strategic segment; sweet spot at $1.9B; very short runway (1.0 qtrs); 95% evidence confidence.
8. KOD - Kodiak Sciences Inc | Score 0.372 | Confidence 95%
Why here: Phase III positive/near-term catalyst; provisional evidence; Ophthalmology / retina strategic segment; sweet spot at $1.9B; very short runway (1.0 qtrs).
9. NRIX - Nurix Therapeutics Inc | Score 0.354 | Confidence 100%
Why here: Oncology / hematology strategic segment; sweet spot at $1.5B; financing pressure (2.0 qtrs); 100% evidence confidence.
10. OLMA - Olema Pharmaceuticals Inc | Score 0.354 | Confidence 95%
Why here: Oncology / hematology strategic segment; sweet spot at $900M; financing pressure (3.3 qtrs); 95% evidence confidence.
11. BHVN - Biohaven Ltd | Score 0.354 | Confidence 100%
Why here: Phase III readout within 12 months; provisional evidence; Neurology / CNS strategic segment; sweet spot at $1.6B; very short runway (1.0 qtrs).
12. ALMS - Alumis Inc | Score 0.354 | Confidence 100%
Why here: Phase III readout within 12 months; provisional evidence; Immunology / rare inflammation strategic segment; acquirable at $2.4B; very short runway (1.3 qtrs).
13. RCUS - Arcus Biosciences Inc | Score 0.337 | Confidence 100%
Why here: Phase II readout within 12 months; provisional evidence; Oncology / hematology strategic segment; acquirable at $2.9B; very short runway (1.7 qtrs).
14. RZLT - Rezolute Inc | Score 0.321 | Confidence 100%
Why here: Phase III readout within 12 months; provisional evidence; Oncology / hematology strategic segment; sweet spot at $410M; very short runway (1.7 qtrs).
15. ABVX - Abivax SA | Score 0.313 | Confidence 90%
Why here: Positive Phase III UC maintenance data; NDA path Q4 2026; source-backed evidence; Immunology / rare inflammation strategic segment; upper acquirable range at $7.4B; moderate runway (5.3 qtrs).
16. CGON - CG Oncology Inc | Score 0.305 | Confidence 95%
Why here: Phase III readout within 12 months; provisional evidence; Oncology / hematology strategic segment; acquirable at $5.0B; moderate runway (6.7 qtrs).
17. CRVS - Corvus Pharmaceuticals Inc | Score 0.305 | Confidence 95%
Why here: Phase II readout within 12 months; provisional evidence; Oncology / hematology strategic segment; sweet spot at $940M; moderate runway (6.7 qtrs).
18. ALLO - Allogene Therapeutics Inc | Score 0.305 | Confidence 100%
Why here: Phase II readout within 12 months; provisional evidence; Oncology / hematology strategic segment; sweet spot at $650M; financing pressure (2.3 qtrs).
19. KURA - Kura Oncology Inc | Score 0.289 | Confidence 100%
Why here: Oncology / hematology strategic segment; sweet spot at $780M; moderate runway (6.7 qtrs); 100% evidence confidence.
20. CELC - Celcuity Inc | Score 0.289 | Confidence 95%
Why here: Oncology / hematology strategic segment; acquirable at $4.3B; financing pressure (2.3 qtrs); 95% evidence confidence.

.dark-mode .Gv0k0K{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .Gv0k0K{ color: #333333; background-color: white; border: 2px solid #333333; }KODKodiak Sciences Inc Common Stockstock NASDAQ

KOD
Kodiak Sciences Inc Common Stock
stock NASDAQ